Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability
- 104 Downloads
Present study was aimed to increase the oral bioavailability and reduce the fast fed variability of Ibrutinib by developing nanosuspension by simple precipitation-ultrasonication method. A three factor, three level, box-behnken design was used for formulation optimization using pluronic F-127 as stabilizer. Size and polydispersity index of the developed formulations were in the range of 278.6 to 453.2 nm and 0.055 to 0.198, respectively. Field emission scanning electron microscope (FESEM) revealed discrete units of nanoparticles. Further, differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) studies confirmed the transformation of crystal drug to amorphous. The amorphous nature was retained after 6-month storage at room temperature. Size reduction to nano range and polymorphic transformation (crystalline to amorphous) increased the solubility of nanosuspension (21.44-fold higher as compared to plain drug). In vivo studies of plain drug suspension displayed a significant pharmacokinetic variation between fasting and fed conditions. The formulation had shown increased Cmax (3.21- and 3.53-fold), AUC0-t (5.21- and 5.83-fold) in fasting and fed states compared to that of values obtained for plain drug in fasting state (Cmax 48.59 ± 3.30 ng/mL and AUC0-t 137.20 ± 35.47 ng.h/mL). Significant difference was not observed in the pharmacokinetics of nanosuspension in fasting and fed states. The formulation had improved solubility in the intestinal pH, which might be the driving force behind the decreased precipitation and increased absorption at intestinal region. Optimistic results demonstrated nanosuspension as a promising approach for increasing the solubility, extent of absorption and diminishing the fast fed variability.
KEY WORDSBox-Behnken design Damkohler number precipitation-ultrasonication method re-dispersibility index solvent anti-solvent ratio
The authors would like to thank NIPER-HYD and Department of Pharmaceuticals (DoP) for providing the facilities and for funding the research work.
The NIPER-HYD and Department of Pharmaceuticals (DoP) provided funding for the research work.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 6.EMA. CHMP assessment report: European Medicines Agency; 2014. https://www.ema.europa.eu/en/documents/assessment-report/imbruvica-epar-public-assessment-report_en.pdf.
- 12.He J, Han Y, Xu G, Yin L, Neubi MN, Zhou J, et al. Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement. RSC Adv. 2017;7(22):13053–64.Google Scholar
- 17.Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci. 2014;4(2):189–97.Google Scholar
- 18.Reverchon E. Supercritical antisolvent precipitation of micro-and nano-particles. J Supercrit Fluids. 1999;15(1):1–21.Google Scholar
- 19.Pathak P, Meziani MJ, Desai T, Sun Y-P. Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercrit Fluids. 2006;37(3):279–86.Google Scholar
- 31.Mishra V, Kesharwani P, Amin MC, Iyer A, editors. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Academic Press; 2017 May 23Google Scholar
- 33.Shah P, Mashru R, Rane Y, Badhan A. Design and optimization of artemether microparticles for bitter taste masking. Acta Pharma. 2008;58(4):379–92.Google Scholar
- 34.Kan S, Lu J, Liu J, Wang J, Zhao Y. A quality by design (QbD) case study on enteric-coated pellets: screening of critical variables and establishment of design space at laboratory scale. AJPS. 2014;9(5):268–78.Google Scholar
- 37.Shariare MH, Sharmin S, Jahan I, Reza H, Mohsin K. The impact of process parameters on carrier free paracetamol nanosuspension prepared using different stabilizers by antisolvent precipitation method. J Drug Deliv Sci Technol. 2018;43:122–8.Google Scholar
- 41.Kho K, Cheow WS, Lie RH, Hadinoto K. Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy. Powder Technol. 2010;203(3):432–9.Google Scholar
- 42.Afifi SA, Hassan MA, Abdelhameed AS, Elkhodairy KA. Nanosuspension: an emerging trend for bioavailability enhancement of etodolac. Int J Polym Sci. 2015;2015:1–16.Google Scholar
- 50.Dalvi SV, Dave RN. Controlling particle size of a poorly water-soluble drug using ultrasound and stabilizers in antisolvent precipitation. Ind Eng Chem Res. 2009;48(16):7581–93.Google Scholar
- 51.Kakran M, Sahoo NG, Tan I-L, Li L. Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods. J Nanopart Res. 2012;14(3):757.Google Scholar
- 55.Pitto-Barry A, Barry NP. Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. Polym Chem. 2014;5(10):3291–7.Google Scholar
- 56.Shaarani S, Hamid SS, Kaus NHM. The influence of Pluronic F68 and F127 nanocarrier on physicochemical properties, in vitro release, and antiproliferative activity of Thymoquinone drug. Pharm Res. 2017;9(1):12.Google Scholar
- 57.Chouhan P, Saini T. D-optimal design and development of microemulsion based transungual drug delivery formulation of ciclopirox olamine for treatment of onychomycosis. Indian J Pharm Sci. 2016;78(4):498–511.Google Scholar
- 58.Lin Y, Alexandridis P. Temperature-dependent adsorption of Pluronic F127 block copolymers onto carbon black particles dispersed in aqueous media. J Phys Chem B. 2002;106(42):10834–44.Google Scholar
- 59.Instruments M. Zetasizer nano series user manual. MAN0317. 2004;1:2004.Google Scholar
- 60.Hassani S, Laouini A, Fessi H, Charcosset C. Preparation of chitosan–TPP nanoparticles using microengineered membranes–effect of parameters and encapsulation of tacrine. Colloids Surf A Physicochem Eng Asp. 2015;482:34–43.Google Scholar
- 63.Chen Z, Zhai J, Liu X, Mao S, Zhang L, Rohani S, et al. Solubility measurement and correlation of the form a of ibrutinib in organic solvents from 278.15 to 323.15 K. J Chem Thermodyn. 2016;103:342–8.Google Scholar
- 64.Eloy JO, Marchetti JM. Solid dispersions containing ursolic acid in Poloxamer 407 and PEG 6000: a comparative study of fusion and solvent methods. Powder Technol. 2014;253:98–106.Google Scholar
- 66.Karolewicz B, Gajda M, Górniak A, Owczarek A, Mucha I. Pluronic F127 as a suitable carrier for preparing the imatinib base solid dispersions and its potential in development of a modified release dosage forms. J Therm Anal Calorim. 2017;130(1):383–90.Google Scholar
- 67.Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229–37.Google Scholar